We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-27.93%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$58.1M
Cap. Flow
+$214K
Cap. Flow %
0.2%
Top 10 Hldgs %
90.19%
Holding
19
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$214K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 89.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$19.7M 18.31%
1,301,413
– –
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
$19M 17.69%
2,080,595
– –
TARA icon
3
Protara Therapeutics
TARA
$230M
$15.6M 14.46%
50,447
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$15M 13.98%
219,901
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
$6.72M 6.25%
383,935
– –
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.06M 4.7%
945,757
– –
TBRA
7
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$4.79M 4.45%
589,244
– –
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$4.67M 4.34%
555,555
– –
EVAR
9
DELISTED
Lombard Medical, Inc.
EVAR
$3.75M 3.49%
3,473,452
– –
CLLS
10
Cellectis
CLLS
$271M
$2.73M 2.54%
100,000
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$2.27M 2.1%
2,728
– –
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$2.16M 2.01%
1,600,000
– –
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
$2.03M 1.88%
250,000
– –
ANTH
14
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.58M 1.47%
54,749
– –
DERM
15
DELISTED
Dermira, Inc.
DERM
$1.45M 1.35%
70,000
– –
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
$533K 0.5%
215,000
– –
ACHV icon
17
Achieve Life Sciences
ACHV
$667M
$271K 0.25%
180
– –
AUPH icon
18
Aurinia Pharmaceuticals
AUPH
$2.01B
$256K 0.24%
+88,307
New +$214K
EPRS
19
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$21K 0.02%
7,896
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2016 Portfolio in Review

As of Q1 2016, Abingworth held 19 positions worth $108M, down 35% from $166M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Abingworth's Q1 2016 filing shows 1 new position. Its largest new stake was Aurinia Pharmaceuticals: 88,307 shares worth $256K.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier.

  • Abingworth's largest Q1 2016 buy was Aurinia Pharmaceuticals: 88,307 shares worth $256K.
  • Abingworth's ten largest holdings make up 90% of its $108M portfolio in Q1 2016.
  • Abingworth opened 1 new position and closed 0 in Q1 2016.
  • Abingworth's portfolio value fell 35% quarter-over-quarter to $108M.

Based on Abingworth's 13F filing for Q1 2016, filed 13 May 2016.